Amgen's aggressive legal pursuit of Sanofi and Regeneron's Praluent might work, but will the PCSK9 developers ever recoup their costs?
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
Patent expiries and challenges have done little to halt the sales of some of the industry's biggest products.
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
A handful of tumour types have disproportionately benefited from the sector’s huge push into oncology. Is the investment case weakening in certain areas?
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
Up-front fees paid out by biopharma companies to seal licensing deals noticeably dipped in the second quarter of the year – then Gilead and Galapagos came along.
2019’s second mega-merger has emerged, and Vantage has crunched some EvaluatePharma data to help dissect the proposed deal.
On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.